**Pharmacokinetics (PK)** is often described as **"what the body does to a drug"** — in contrast to pharmacodynamics, which is "what the drug does to the body."
It tracks the journey of a medication from the moment it enters your system until it completely leaves.
## The Four Main Stages: ADME
Pharmacokinetics centers on four core processes, commonly remembered by the acronym **ADME**:
### 1. Absorption (How will it get in?)
How the drug moves from its site of administration (e.g., swallowed pill, skin patch, injection) into the bloodstream.
* **Key factors:** Route of administration, oral bioavailability (F), and stomach acidity.
* **Note:** Drugs given via IV skip this phase entirely because they are injected directly into systemic circulation (F = 100\%).
### 2. Distribution (Where will it go?)
How the drug spreads throughout body tissues and fluids via the circulatory system.
* **Key factors:** Blood flow to target tissues, tissue permeability, and binding to plasma proteins (like albumin). Unbound or "free" drug is what actually produces therapeutic effects.
* **Volume of Distribution (V_d):** A theoretical volume reflecting how extensively a drug spreads into body tissues vs. remaining in the blood.
### 3. Metabolism (How is it broken down?)
The chemical transformation of the drug by the body, converting active substances into water-soluble metabolites for easier elimination.
* **Primary location:** Liver (via enzymes such as the Cytochrome P450 family).
* **First-Pass Effect:** Oral medications pass directly from the digestive tract to the liver via the portal vein, where a portion is broken down before ever reaching the rest of the body.
### 4. Excretion (How does it leave?)
The removal of the drug and its metabolites from the body.
* **Primary location:** Kidneys (via urine).
* **Other routes:** Bile/feces, exhalation, sweat, or breast milk.
## Essential Quantitative Parameters
| Parameter | Symbol | What It Measures |
|---|---|---|
| **Half-Life** | t_{1/2} | Time required for the plasma concentration of a drug to decrease by 50%. |
| **Clearance** | CL | Volume of plasma cleared of the drug per unit time (e.g., mL/min). |
| **Bioavailability** | F | Percentage of the administered dose that reaches systemic circulation intact. |
| **Area Under the Curve** | AUC | Total integrated drug exposure in systemic circulation over time. |
**Clinical pharmacokinetics** is the discipline that applies fundamental pharmacokinetic concepts to safely and effectively manage drug therapy in individual patients. In simple terms: while **pharmacodynamics** focuses on *what the drug does to the body*, **pharmacokinetics** tracks *what the body does to the drug* over time.
The core goal is to keep plasma drug concentrations within the **therapeutic window**—above the minimum effective concentration (MEC) to ensure efficacy, but below the minimum toxic concentration (MTC) to prevent adverse reactions.
## 1. The Core ADME Framework
Drug behavior in the body is broken down into four major steps:
* **Absorption:** How the drug enters systemic circulation from its route of administration (e.g., oral, intravenous, transdermal).
* **Distribution:** How the drug moves from the bloodstream into extracellular fluids, tissues, and target sites.
* **Metabolism:** The biotransformation of the drug (primarily in the liver via Phase I and Phase II reactions) into active or inactive metabolites.
* **Excretion:** The permanent removal of the drug or its metabolites from the body (mainly via the kidneys/urine, bile, or feces).
## 2. Key Mathematical Parameters
To design precise dosing regimens, clinicians rely on four fundamental parameters:
### Clearance (CL)
Clearance is the single most important parameter in long-term therapy. It represents the volume of plasma cleared of the drug per unit time. It determines the **maintenance dose rate** required to maintain a target steady-state concentration (C_{ss}):
### Volume of Distribution (V_d)
V_d relates the total amount of drug in the body (A_b) to its concentration in plasma (C_p):
It reflects how extensively a drug distributes into body tissues versus remaining in blood plasma. High V_d indicates wide tissue distribution (e.g., lipophilic drugs like diazepam). V_d determines the **loading dose** required to reach a target concentration immediately:
### Elimination Half-Life (t_{1/2})
The time required for plasma concentration to decrease by 50%. It depends directly on clearance and volume of distribution:
* **Steady State:** It takes approximately **4 to 5 half-lives** of continuous or regular dosing to reach a stable level (steady state) in the body.
### Bioavailability (F)
The fraction of the administered dose that reaches systemic circulation in active form (expressed as a decimal or percentage). For intravenous (IV) administration, F = 1 (100%). For oral drugs, first-pass liver metabolism often reduces F.
## 3. Clinical Applications & Individualization
Because patients vary by age, genetics, weight, and organ function, standard "one-size-fits-all" dosing is often insufficient.
```
Patient Variables (Age, Weight, Renal/Liver Function)
│
▼
Initial Pharmacokinetic Dosing Model
│
▼
Therapeutic Drug Monitoring (Serum Levels)
│
▼
Dose Adjustment (Bayesian Methods / Clearance)
```
1. **Renal Impairment:** Drugs eliminated by the kidneys (e.g., vancomycin, aminoglycosides, digoxin) require dose reductions or longer dosing intervals when creatinine clearance (CL_{cr}) drops.
2. **Hepatic Impairment:** Liver dysfunction slows drug metabolism, increasing half-life and risk of toxicity.
3. **Therapeutic Drug Monitoring (TDM):** Measuring peak and trough blood concentrations to fine-tune regimens for drugs with narrow therapeutic windows (e.g., phenytoin, lithium, vancomycin, gentamycin).
